EDITORIAL SECTION

Imviva Biotech a clinicalstage biotechnology company developing nextgeneration allogeneic CART cell therapies today announced that the US Food and Drug Administration FDA has granted authorization

Drug developers have a new optimized option for USbased manufacturing as AGC Biologics enters a strategic partnership with Pyramid Pharma Services The collaboration combines AGC Biologics expertise in drug substance

Zymeworks Inc Nasdaq ZYME the Company a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel multifunctional biotherapeutics

Merck NYSE MRK known as MSD outside of the United States and Canada today announced an agreement with the ADAP Crisis Task Force ACTF to help state AIDS Drug Assistance Programs ADAPs

Insilico Medicine has entered into a strategic collaboration with Takeda to use its proprietary PharmaAI platform to support the discovery and development of new drug candidates across Takedas therapeutic areas

Abbisko Therapeutics has entered into a strategic collaboration with AstraZeneca to jointly advance the clinical development of a new immunooncology and targeted therapy combination for the treatment of nonsmall cell lung cancer NSCLC

Monopar Therapeutics has received Rare Pediatric Disease RPD designation from the US Food and Drug Administration FDA for ALXN tiomolibdate choline its latestage investigational treatment for Wilson disease

Roche has launched AXELIOS a nextgeneration sequencing platform based on its proprietary sequencing by expansion SBX technology The platform combines high accuracy speed flexibility scalability and cost efficiency

Innovent Biologics and Eli Lilly and Company have entered into a distribution and promotion agreement for Verzenios abemaciclib in mainland China

Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for TRYNGOLZA olezarsen as an addon treatment to diet for adults with severe hypertriglyceridaemia sHTG a condition